石墨烯氧化物的肝清除和与大小相关的肝毒性多方面的表征
Zongyi Su1,2, Wei Chen2, Shanshan Liang2,3
1School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China.
较小的石墨烯氧化物 (GO) 片通过肝胆排泄更有效地从肝脏清除,而不是较大的片. 这种增强的小GO清除减轻了肝脏毒性,有助于更安全的纳米材料设计.
科学领域:
- 纳米材料科学是纳米材料科学.
- 肝病学 肝病学是一种肝病学.
- 生物医学工程 生物医学工程
背景情况:
- 石墨烯氧化物 (GO) 是一种具有显著生物医学潜力的二维纳米材料.
- 了解纳米材料在肝脏中的命运对于安全应用至关重要.
- 由于GO在肝脏中积累,因此需要研究其相互作用.
研究的目的:
- 为了研究不同侧面大小的PEGylated石墨烯氧化物 (GO) 的肝脏清除.
- 阐明GO在肝脏中吸收,降解和分泌的机制.
- 评估GO大小对其清除和潜在肝毒性的影响.
主要方法:
- 小 (s-GO, ~70 nm) 和大 (l-GO, ~300 nm) PEGylated GO. 的比较.
- 使用ICP-MS,LA-ICP-MS和同步辐射FTIR进行元素和化学分析.
- 使用拉曼成像来分析GO引起的缺陷 (I_D/I_G比率).
主要成果:
- GO片穿过肝脏的阴影内皮,并被肝细胞吸收.
- 肝细胞可能会将GO降解为更小的颗粒,用于肝胆排泄.
- 较小的GO片 (s-GO) 与较大的GO (l-GO) 相比,通过肝胆排泄显示出更大的清除.
- 无论是s-GO还是l-GO都会诱导肝脏的缺陷.
- 肝脏显微体有助于GO生物转化,增强降解和分泌.
结论:
- 肝脏GO的清除量取决于大小,较小的GO被更有效地清除.
- 有效的s-GO清除可以减轻肝毒性,支持更安全的设计原则.
- 这项研究增强了对生物医学应用软纳米材料肝清除的理解.
相关概念视频
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
Most drugs undergo restrictive clearance, which is proportional to the...
Hepatic Drug Clearance: Role of Transporters
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...


